Asia Pacific Preclinical Imaging Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2023 –2030 |
 Tamanho do mercado (ano base ) | USD 264,195.80 Thousand |
 Tamanho do mercado ( Ano de previsão) | USD 396,436.69 Thousand |
 CAGR |
% |
| Principais participantes do mercado |
Mercado de imagiologia pré-clínica da Ásia-Pacífico, por produto (sistemas e serviços), reagentes (reagentes de imagiologia ótica pré-clínica, reagentes de imagiologia nuclear pré-clínica, agentes de contraste de ressonância magnética pré-clínica, agentes de contraste de ecografia pré-clínica e agentes de contraste de tomografia computorizada pré-clínica), aplicação (investigação e desenvolvimento, Descoberta de fármacos, biodistribuição, deteção de células cancerígenas, biomarcadores e outros), utilizador final (organização de investigação contratada, empresas farmacêuticas e de biotecnologia, institutos de investigação académicos e governamentais, centro de diagnóstico e outros) - Tendências e previsões do sector para 2030 .
Análise e tamanho do mercado de imagens pré-clínicas da Ásia-Pacífico
O mercado de imagiologia pré-clínica da Ásia-Pacífico é a indústria envolvida no fornecimento de soluções e tecnologias de imagiologia para a realização de investigação e experimentação em animais (geralmente roedores) na fase pré-clínica de desenvolvimento de medicamentos e investigação médica. Estas técnicas de imagem são cruciais para avaliar a segurança e eficácia de potenciais candidatos a medicamentos e tratamentos médicos antes de avançarem para ensaios clínicos envolvendo seres humanos. A imagiologia pré-clínica permite aos investigadores e às empresas farmacêuticas avaliar os efeitos dos candidatos a medicamentos nos organismos vivos antes de passarem para testes em humanos. Isto ajuda a identificar possíveis problemas, a otimizar os regimes posológicos e a reduzir o risco de efeitos adversos em fases posteriores.
A Data Bridge Market Research analisa que o mercado de imagiologia pré-clínica da Ásia-Pacífico deverá atingir o valor de 396.436,69 mil dólares até 2030, face aos 264.195,80 mil dólares em 2022, com um CAGR de 5,5% durante o período de previsão.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2015-2020) |
|
Unidades Quantitativas |
Receita em mil dólares |
|
Segmentos cobertos |
Produto (sistemas e serviços), reagentes (reagentes de imagem ótica pré-clínica, reagentes de imagem nuclear pré-clínica, agentes de contraste pré-clínicos para ressonância magnética, agentes de contraste pré-clínicos para ecografia e agentes de contraste pré-clínicos para tomografia computorizada), aplicação (investigação e desenvolvimento, descoberta de fármacos, biodistribuição, cancro Detecção de células, biomarcadores e outros), utilizador final (organização de investigação por contrato, empresas farmacêuticas e de biotecnologia, institutos de investigação académicos e governamentais, centro de diagnóstico e outros) |
|
Países abrangidos |
Japão, China, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Resto da Ásia-Pacífico |
|
Participantes do mercado abrangidos |
PerkinElmer Inc., FUJIFILM Visualsonics, Inc (uma subsidiária da FUJIFILM Corporation), Bruker, Hologic, Inc., ZEISS Group, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd., LI-COR, Inc., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, AI4R e entre outros |
Definição de mercado
A imagiologia pré-clínica é a utilização de várias técnicas e tecnologias de imagem para visualizar e estudar processos biológicos, doenças e respostas a medicamentos em modelos animais antes de serem testados em humanos. Envolve a imagiologia não invasiva de animais, normalmente roedores, como ratinhos e ratos, para obter informações sobre os mecanismos subjacentes das doenças e avaliar a eficácia e segurança de possíveis terapias.
Dinâmica do mercado de imagiologia pré-clínica da Ásia-Pacífico
Motoristas
- Aumento do avanço tecnológico no domínio da imagem
O avanço tecnológico no campo da imagiologia está a desempenhar um papel crucial na condução do crescimento do mercado de imagiologia pré-clínica da Ásia-Pacífico. As modernas tecnologias de imagem, como a ressonância magnética (RM) de alta resolução , a tomografia microcomputadorizada (micro-TC) e a ecografia avançada fornecem aos investigadores imagens mais claras e detalhadas das estruturas biológicas.
Além disso, houve melhorias significativas na análise de imagens e nos algoritmos de processamento de dados. As ferramentas avançadas de software e os algoritmos de aprendizagem automática permitem aos investigadores extrair dados quantitativos de imagens, automatizar tarefas de processamento de imagens e melhorar a precisão e a eficiência da análise de dados. Estes avanços poupam tempo e aumentam a reprodutibilidade e a fiabilidade dos estudos pré-clínicos.
- Número crescente de investimentos e financiamento em investigação e desenvolvimento
O crescente número de investimentos e financiamento em investigação e desenvolvimento (I&D) é um motor significativo do crescimento do mercado de imagiologia pré-clínica da Ásia-Pacífico. As organizações estão a alocar recursos substanciais para o avanço das tecnologias de imagem e para apoiar iniciativas de investigação inovadoras, à medida que a importância da imagem pré-clínica na descoberta e desenvolvimento de medicamentos se torna mais evidente.
Os investimentos e o financiamento em I&D permitem o desenvolvimento de novas modalidades e técnicas de imagiologia pré-clínica. Este apoio financeiro facilita a melhoria dos sistemas de imagem, software e hardware, levando a uma melhor qualidade, resolução e sensibilidade da imagem. Estes avanços permitem aos investigadores obter informações mais precisas e detalhadas sobre os processos biológicos, os mecanismos de doença e as respostas ao tratamento, impulsionando o crescimento do mercado de imagiologia pré-clínica.
Oportunidade
- Aumento da adoção de sistemas de imagem para fins pré-clínicos
As indústrias farmacêutica e biotecnológica estão continuamente à procura de novos candidatos a medicamentos para satisfazer as necessidades médicas não satisfeitas. A imagiologia pré-clínica permite uma compreensão mais abrangente dos potenciais candidatos a medicamentos, visualizando os seus efeitos nos organismos vivos. Isto ajuda a identificar candidatos promissores e a eliminar aqueles com características desfavoráveis no início do processo de desenvolvimento de medicamentos, poupando tempo e recursos. A mudança para a medicina personalizada requer uma compreensão mais profunda das condições individuais dos doentes. A imagiologia pré-clínica pode ser utilizada para avaliar a heterogeneidade da doença e adaptar as abordagens de tratamento, levando a terapias mais eficazes.
Restrição / Desafio
- Estrutura regulamentar rigorosa para aprovação de produtos
As entidades reguladoras de todo o mundo estabeleceram diretrizes e requisitos rigorosos para a aprovação de produtos de imagiologia pré-clínica, o que pode criar barreiras para as empresas do mercado e é um fator de restrição significativo ao crescimento do mercado de imagiologia pré-clínica da Ásia -Pacífico.
O processo regulamentar para produtos de imagem pré-clínicos é demorado e dispendioso. As empresas realizam estudos abrangentes para demonstrar a segurança e eficácia dos seus produtos, o que implica investimentos significativos em investigação e desenvolvimento. Além disso, o processo de submissão regulamentar requer uma extensa documentação, análise de dados e interação com as autoridades reguladoras, o que aumenta o tempo e os custos.
Desenvolvimentos recentes
- Em novembro de 2022, Bruker anunciou a aquisição da Inscopix, Inc., pioneira em neurociência e líder de mercado de microscópios miniaturizados, conhecidos como miniscópios, para imagiologia cerebral de animais em movimento livre. Isto ajudou a organização a gerar mais receitas
- Em maio de 2022, a FUJIFILM Corporation anunciou o lançamento do Vevo F2, o primeiro sistema de ultra-sons e imagem fotoacústica de ultra-alta a baixa frequência (71MHz-1MHz) do mundo para uso pré-clínico. O Vevo F2 possui tecnologia de processamento de imagem HD e introduz um caminho de sinal completamente novo – do transdutor ao ecrã. Isto permitiu uma melhor clareza de imagem e, quando combinado com o processamento multilinha, oferece taxas de fotogramas significativamente melhores em relação às plataformas da geração anterior
Âmbito do mercado de imagens pré-clínicas da Ásia-Pacífico
O mercado de imagiologia pré-clínica da Ásia-Pacífico está segmentado em quatro segmentos notáveis com base em produtos, reagentes, aplicação e utilizador final. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Produto
- Sistemas
- Serviços
Com base no produto, o mercado está segmentado em sistemas e serviços.
Reagentes
- Reagentes de imagem óptica pré-clínica
- Reagentes de imagem nuclear pré-clínica
- Agentes de contraste pré-clínicos para ressonância magnética
- Agentes de contraste pré-clínicos para ecografia
- Agentes de contraste pré-clínicos para tomografia computorizada
Com base em reagentes, o mercado está segmentado em reagentes de imagem ótica pré-clínicos, reagentes de imagem nuclear pré-clínicos, agentes de contraste de ressonância magnética pré-clínicos, agentes de contraste de ultrassons pré-clínicos e agentes de contraste de tomografia computadorizada pré-clínicos.
Aplicação
- Investigação e Desenvolvimento
- Descoberta de fármacos
- Biodistribuição
- Detecção de células cancerígenas
- Biomarcadores
- Outros
Com base na aplicação, o mercado está segmentado em investigação e desenvolvimento, descoberta de fármacos, biodistribuição, deteção de células cancerígenas, biomarcadores, entre outros.
Utilizador final
- Organização de investigação contratada
- Empresas farmacêuticas e de biotecnologia
- Institutos de Investigação Académica e Governamental
- Centro de Diagnóstico
- Outros
Com base no utilizador final, o mercado está segmentado em organizações de investigação por contrato, empresas farmacêuticas e de biotecnologia, institutos de investigação académicos e governamentais, centro de diagnóstico, entre outros.
Análise/perspetivas regionais do mercado de imagiologia pré-clínica da Ásia-Pacífico
O mercado de imagiologia pré-clínica da Ásia-Pacífico está segmentado em quatro segmentos notáveis com base em produtos, reagentes, aplicação e utilizador final.
Os países abrangidos neste relatório de mercado são o Japão, China, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Resto da Ásia-Pacífico.
Espera-se que a China domine o mercado devido à crescente procura de dispositivos de imagem. A China é o país que mais cresce no mercado, com a maior quota de mercado devido ao aumento dos avanços tecnológicos.
A secção do relatório sobre países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas, análise das cinco forças de Porter e estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas regionais e os desafios enfrentados devido à concorrência grande ou escassa de marcas regionais, o impacto das tarifas nacionais e as rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país .
Análise do panorama competitivo e da quota de mercado de imagiologia pré-clínica da Ásia-Pacífico
O panorama competitivo do mercado de imagens pré-clínicas fornece detalhes do concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, largura e amplitude do produto e domínio de aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.
Alguns dos principais players do mercado que operam no mercado de imagiologia pré-clínica da Ásia-Pacífico são a PerkinElmer Inc., a FUJIFILM Visualsonics, Inc (uma subsidiária da FUJIFILM Corporation), a Bruker, a Hologic, Inc., o ZEISS Group, a Agilent Technologies, Inc ., Hamamatsu Photonics KK, Vieworks Co., Ltd., LI-COR, Inc., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd., IVIM Technology Inc., MR Solutions, AI4R e entre outros .
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC PRECLINICAL IMAGING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FIRCES
4.3 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
5.1 REGULATORY SCENARIO IN AUSTRALIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF IMAGING
6.1.2 INCREASING NUMBER OF INVESTMENTS AND FUNDING IN RESEARCH AND DEVELOPMENT
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY FRAMEWORK FOR PRODUCT APPROVAL
6.2.2 HIGH INSTALLATION AND OPERATIONAL COST OF PRECLINICAL IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 INCREASING ADOPTION OF IMAGING SYSTEMS FOR PRECLINICAL PURPOSES
6.3.2 GROWING DEMAND FOR NON-INVASIVE SMALL-ANIMAL IMAGING METHODS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS FOR THE EFFECTIVE UTILIZATION OF PRECLINICAL IMAGING SYSTEMS
6.4.2 INTEGRATION OF IMAGING DEVICES WITH OTHER TECHNOLOGIES
7 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 SYSTEMS
7.2.1 OPTICAL IMAGING SYSTEMS
7.2.1.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS
7.2.1.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS
7.2.1.3 OPTICAL + X-RAY/OPTICAL + CT
7.2.2 PRECLINICAL NUCLEAR IMAGING SYSTEMS
7.2.2.1 MICRO-POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS
7.2.2.2 MICRO-SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SYSTEMS
7.2.2.3 TRIPRODUCT (SPECT/PET/CT) SYSTEMS
7.2.3 MICRO-MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
7.2.4 MICRO-COMPUTED TOMOGRAPHY (CT) SYSTEMS
7.2.5 MICRO-ULTRASOUND SYSTEMS
7.2.6 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS
7.2.7 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS
7.2.8 MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI)
7.3 SERVICES
8 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY REAGENTS
8.1 OVERVIEW
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS
8.2.1 BIOLUMINESCENT IMAGING REAGENTS
8.2.2 FLUORESCENT IMAGING REAGENTS
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS
8.3.1 PRECLINICAL PET TRACERS
8.3.2 PRECLINICAL SPECT PROBES
8.4 PRECLINICAL MRI CONTRAST AGENTS
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.2 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.3 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS
8.6 PRECLINICAL CT CONTRAST AGENTS
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.3 GOLD NANOPARTICLES
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS
9 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 RESEARCH AND DEVELOPMENT
9.3 DRUG DISCOVERY
9.4 BIO-DISTRIBUTION
9.5 CANCER CELL DETECTION
9.6 BIO-MARKERS
9.7 OTHERS
10 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL & BIOTECH COMPANIES
10.4 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
10.5 DIAGNOSTICS CENTER
10.6 OTHERS
11 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY COUNTRY
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 SOUTH KOREA
11.1.4 INDIA
11.1.5 AUSTRALIA
11.1.6 SINGAPORE
11.1.7 THAILAND
11.1.8 MALAYSIA
11.1.9 INDONESIA
11.1.10 PHILIPPINES
11.1.11 RSET OF ASIA PACIFIC
12 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 PERKINELMER INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 FUJIFILM VISUALSONICS, INC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 HOLOGIC, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BRUKER
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 ZEISS GROUP
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ADVANCED MOLECULAR VISION, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 AGILENT TECHNOLOGIES, INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 AI4R
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BERTHOLD TECHNOLOGIES GMBH & CO.KG
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 HAMAMATSU PHOTONICS K.K.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 IVIM TECHNOLOGY CORP.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 LI-COR, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 MEDISO LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILABS B.V.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MR SOLUTIONS
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 PHOTON ETC
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 TRIFOIL IMAGING
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 VIEWORKS CO., LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 13 CHINA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 14 CHINA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 15 CHINA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 16 CHINA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 17 CHINA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 18 CHINA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 19 CHINA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 20 CHINA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 21 CHINA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 22 CHINA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 23 CHINA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 24 CHINA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 25 CHINA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 26 CHINA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 27 CHINA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 28 CHINA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 29 CHINA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 30 CHINA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 31 CHINA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 32 CHINA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 33 CHINA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 34 CHINA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 35 CHINA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 36 CHINA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 37 CHINA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 38 CHINA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 39 CHINA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 40 JAPAN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 41 JAPAN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 42 JAPAN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 43 JAPAN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 44 JAPAN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 45 JAPAN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 46 JAPAN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 47 JAPAN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 48 JAPAN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 49 JAPAN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 50 JAPAN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 51 JAPAN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 52 JAPAN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 53 JAPAN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 54 JAPAN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 55 JAPAN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 56 JAPAN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 57 JAPAN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 58 JAPAN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 59 JAPAN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 60 JAPAN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 61 JAPAN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 62 JAPAN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 63 JAPAN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 64 JAPAN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 65 JAPAN PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 66 JAPAN PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 67 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 68 SOUTH KOREA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 69 SOUTH KOREA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 70 SOUTH KOREA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 71 SOUTH KOREA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 72 SOUTH KOREA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 73 SOUTH KOREA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 74 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 75 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 76 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 77 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 78 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 79 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 80 SOUTH KOREA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 81 SOUTH KOREA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 82 SOUTH KOREA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 83 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 84 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 85 SOUTH KOREA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 86 SOUTH KOREA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 87 SOUTH KOREA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 88 SOUTH KOREA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 89 SOUTH KOREA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 90 SOUTH KOREA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 91 SOUTH KOREA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 92 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 93 SOUTH KOREA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 94 INDIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 95 INDIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 96 INDIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 97 INDIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 98 INDIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 99 INDIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 100 INDIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 101 INDIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 102 INDIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 103 INDIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 104 INDIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 105 INDIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 106 INDIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 107 INDIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 108 INDIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 109 INDIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 110 INDIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 111 INDIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 112 INDIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 113 INDIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 114 INDIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 115 INDIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 116 INDIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 117 INDIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 118 INDIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 119 INDIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 120 INDIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 121 AUSTRALIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 122 AUSTRALIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 123 AUSTRALIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 124 AUSTRALIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 125 AUSTRALIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 126 AUSTRALIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 127 AUSTRALIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 128 AUSTRALIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 129 AUSTRALIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 130 AUSTRALIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 131 AUSTRALIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 132 AUSTRALIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 133 AUSTRALIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 134 AUSTRALIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 135 AUSTRALIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 136 AUSTRALIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 137 AUSTRALIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 138 AUSTRALIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 139 AUSTRALIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 140 AUSTRALIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 141 AUSTRALIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 142 AUSTRALIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 143 AUSTRALIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 144 AUSTRALIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 145 AUSTRALIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 146 AUSTRALIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 147 AUSTRALIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 148 SINGAPORE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 149 SINGAPORE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 150 SINGAPORE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 151 SINGAPORE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 152 SINGAPORE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 153 SINGAPORE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 154 SINGAPORE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 155 SINGAPORE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 156 SINGAPORE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 157 SINGAPORE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 158 SINGAPORE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 159 SINGAPORE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 160 SINGAPORE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 161 SINGAPORE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 162 SINGAPORE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 163 SINGAPORE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 164 SINGAPORE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 165 SINGAPORE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 166 SINGAPORE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 167 SINGAPORE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 168 SINGAPORE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 169 SINGAPORE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 170 SINGAPORE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 171 SINGAPORE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 172 SINGAPORE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 173 SINGAPORE PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 174 SINGAPORE PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 175 THAILAND PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 176 THAILAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 177 THAILAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 178 THAILAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 179 THAILAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 180 THAILAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 181 THAILAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 182 THAILAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 183 THAILAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 184 THAILAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 185 THAILAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 186 THAILAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 187 THAILAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 188 THAILAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 189 THAILAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 190 THAILAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 191 THAILAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 192 THAILAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 193 THAILAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 194 THAILAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 195 THAILAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 196 THAILAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 197 THAILAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 198 THAILAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 199 THAILAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 200 THAILAND PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 201 THAILAND PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 202 MALAYSIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 203 MALAYSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 204 MALAYSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 205 MALAYSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 206 MALAYSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 207 MALAYSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 208 MALAYSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 MALAYSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 210 MALAYSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 211 MALAYSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 212 MALAYSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 213 MALAYSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 214 MALAYSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 215 MALAYSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 216 MALAYSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 217 MALAYSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 218 MALAYSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 219 MALAYSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 220 MALAYSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 221 MALAYSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 222 MALAYSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 223 MALAYSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 224 MALAYSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 225 MALAYSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 226 MALAYSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 227 MALAYSIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 228 MALAYSIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 229 INDONESIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 230 INDONESIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 231 INDONESIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 232 INDONESIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 233 INDONESIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 234 INDONESIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 235 INDONESIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 236 INDONESIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 237 INDONESIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 238 INDONESIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 239 INDONESIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 240 INDONESIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 241 INDONESIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 242 INDONESIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 243 INDONESIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 244 INDONESIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 245 INDONESIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 246 INDONESIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 247 INDONESIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 248 INDONESIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 249 INDONESIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 250 INDONESIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 251 INDONESIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 252 INDONESIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 253 INDONESIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 254 INDONESIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 INDONESIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 256 PHILIPPINES PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 257 PHILIPPINES SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 258 PHILIPPINES SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 259 PHILIPPINES SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 260 PHILIPPINES OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 261 PHILIPPINES OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 262 PHILIPPINES OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 263 PHILIPPINES PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 264 PHILIPPINES PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 265 PHILIPPINES PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 266 PHILIPPINES PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 267 PHILIPPINES PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 268 PHILIPPINES PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 269 PHILIPPINES PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 270 PHILIPPINES PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 271 PHILIPPINES PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 272 PHILIPPINES PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 273 PHILIPPINES PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 274 PHILIPPINES PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 275 PHILIPPINES PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 276 PHILIPPINES PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 277 PHILIPPINES PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 278 PHILIPPINES PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 279 PHILIPPINES PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 280 PHILIPPINES PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 281 PHILIPPINES PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 282 PHILIPPINES PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 283 REST OF ASIA-PACIFIC PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
Lista de Figura
FIGURE 1 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF CHRONIC DISORDERS AND ADVANCEMENTS IN IMAGING TECHNIQUES ARE DRIVING THE GROWTH OF THE ASIA-PACIFIC PRECLINICAL IMAGING MARKET FROM 2023 TO 2030
FIGURE 12 SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC PRECLINICAL IMAGING MARKET
FIGURE 14 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, 2022
FIGURE 15 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, 2023-2030 (USD THOUSAND)
FIGURE 16 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 17 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, 2022
FIGURE 19 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, 2023-2030 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, CAGR (2023-2030)
FIGURE 21 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY REAGENTS, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, 2022
FIGURE 23 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, 2022
FIGURE 27 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: SNAPSHOT (2022)
FIGURE 31 ASIA-PACIFIC PRECLINICAL IMAGING MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
